« Dr. John Charles, Deputy Chief Scientist for Bioastronautics, Space Life Sciences Directorate, NASA Johnson Space Center, 10/19/05 | Main | Dr. Michael Liebman, Executive Director, Windber Research Institute, 11/30/05 »
December 01, 2005
Dr. Jan Tornell, Global Director, AstraZeneca Transgenics and Comparative Genomics, 11/30/05
Dr. Tornell is Global Director of AstraZeneca Transgenics and Comparative Genomics. In 1996 he was recruited to Astra to build and lead a core unit (Astra Transgenic Centre) to generate and analyze transgenic models for the company worldwide. Prior to joining AstraZeneca Dr. Tornell ran a research group at Gothenburg University. He has had a leading role in building the transgenic technology in Scandinavia.
AstraZeneca has a powerful product portfolio including many world leaders and a range of high potential therapies for treating cancer (Casodex, Arimidex, Faslodex), gastrointestinal disease (Nexium), asthma (Symbicort), hypertension (Atacand), high cholesterol (Crestor), migraine (Zomig), and schizophrenia (Seroque ). Sales in 2004 totalled $21.4 billion.
In R&D AstraZeneca spends over $15 million every working day ($3.8 billion in 2004). In Discovery, Company scientists focus on finding new compounds with high potential as new medicines, working across boundaries to exchange ideas, to share best practices, and to make the most of the efficiencies offered by global collaboration.
AstraZeneca’s corporate HQ is in London and the R&D HQ is in Södertälje, Sweden. The Company has a strong presence in the U.S. and is active worldwide with sales in over 100 countries, manufacturing in 20, and major research centers in seven. In total AstraZeneca has over 64,000 employees worldwide.
Posted by David Lemberg at December 1, 2005 08:42 AM Return to SCIENCE AND SOCIETY home page